Активные метаболиты витамина D: применениепри остеопорозе

1. Sambrook Ph., Cooper C. Osteoporosis. Lancet 2006; 367: 2010-2018.

2. Бащинский С.Е. Методическое пособие по разработке клинических практических руководств. Москва, 2003.

3. Institute for Clinical Systems Improvement (ICSI) Health Care Guideline for Patients and Families. July 2006.

4. Gillespie et al. Vitamin D and vitamin D analogues for preventing fractures, associated with involutional and postmenopausal osteoporosis. Gillespie et al. The Cochrane Library, Issue 2, 2004.

5. Papadimitropoulos et al. Meta-Analisis of the Efficacy of Vitamin D Treatmentin Preventing Osteoporosisin Postmenopausal Woman. Endocrine Rewiews 2002; 23 (4): 560-569.

6. Richy F., Ethgen O., Bravere О. et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004 Apr; 15(4): 301-10.

7. Richy F. et al. Vitamin D Analogs Versus Native Vitamin D in Preventing Bone Loss and Osteoporosis-Related Fractures: A Comparative Meta-analysis. Calcif Tissue Int. 2005; 76: 176-186.

8. De Nijs R.N., Jacobs J.W., Algra A. et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004; 15(8): 589-602.

9. El-Agroudy AE et al. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003 Nov; 14(11): 2975-9.

10. Torres A. et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004 Feb; 65(2): 705-12.

11. De Sevaux R.G. et al. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002 Jun; 13 (6): 1608-14.

12. Ringe J.D. et al. Superiority of combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007; 27: 425-434.

13. Masud T. et al. Effects of cyclical etidronatecombined with calcitriol versuscyclical ethidronate aloneon spine and femoral neckbone mineral density in postmenopausal osteoporotic women. Ann.Rheum.Dis. 1998; 57: 346-349.

14. Barone A. et al. Secondary Hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J. Am.Geriatr.Soc. 2007; 55(5): 752-7.

15. Ones K., Schacht E., Dukas L., Caglar N. Effecrs of Comdinet Treatment with Alendronate and Alfacalcidol on Bone Mineral Density and Bone Turnover in Postmenopausal Osteoporosis: A two-years, randomized, multiarm, controlled trial. The Internet Jornal of Epidemiology 2007; Vol 4, Number 1.

16. Ducas L. et al. Alfacalcidol Reduces the Number of Fallers in a Community-Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 mg Daily. JAGS. 2004; 52: 230-236.

17. Ducas L. et al. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporosis Int. 2005; 16(2): 198-203.

18. Heike A. et al. Effect of Vitamin D on falls. A metaanalysis. JAMA. 2004; 291: 1999-2006.

19. Gallagher J.C. An Age-Related Decrease in Creatinine Clearance Is Associated with Increasein Number of Fallsin Untreated Women But Not in Women Receiving Calcitriol Treatment. J of Clinical Endocrinology Metab. 2007; 92(1): 51-58.

20. Richy F. et al. Differential effects of D-gormon analogs and native vitamin D on the risk of falls: a comparative metaanalysis. Calcif. Tissue Int. 2008; 82(2): 102-7.

21. Avenel A. et al. Vitamin D and Vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev. 2005; 20 (3): CD000227.